Shinichi Ikushiro

Prof. Shinichi Ikushiro

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HIHideyuki Inui
Hideyuki Inui
TIToshimasa Itoh
Toshimasa Itoh
KYKeiko Yamamoto
Keiko Yamamoto
SIShinichi Ikushiro
Shinichi Ikushiro
Toshiyuki SakakiToshiyuki Sakaki
Toshiyuki Sakaki
Polychlorinated dibenzo-p-dioxins (PCDDs) and coplanar polychlorinated biphenyls (PCBs) contribute to dioxin toxicity in humans and wildlife after bioaccumulation through the food chain from the environment. The authors examined human and rat cytochrome P450 (CYP)-dependent metabolism of PCDDs and PCBs. A number of human CYP isoforms belonging to the CYP1 and CYP2 families showed remarkable activities toward low-chlorinated PCDDs. In particular, human CYP1A1, CYP1A2, and CYP1B1 showed high activities toward monoCDDs, diCDDs, and triCDDs but no detectable activity toward 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-tetraCDD). Large amino acids located at putative substrate-recognition sites and the F-G loop in rat CYP1A1 contributed to the successful metabolism of 2,3,7,8-tetraCDD. Rat, but not human, CYP1A1 metabolized 3,3',4,4',5-pentachlorobiphenyl (CB126) to two hydroxylated metabolites. These metabolites are probably less toxic than is CB126, due to their higher solubility. Homology models of human and rat CYP1A1s and CB126 docking studies indicated that two amino acid differences in the CB126-binding cavity were important for CB126 metabolism. In this review, the importance of CYPs in the metabolism of dioxins and PCBs in mammals and the species-based differences between humans and rats are described. In addition, the authors reveal the molecular mechanism behind the binding modes of dioxins and PCBs in the heme pocket of CYPs.

30 March 2023 in Molecules
Verified
Journal Article
Open access
PDF file
SCSeita Chudan
Seita Chudan
RIRiko Ishibashi
Riko Ishibashi
MNMiyu Nishikawa
Miyu Nishikawa
YTYoshiaki Tabuchi
Yoshiaki Tabuchi
Yoshinori NagaiYoshinori Nagai
Yoshinori Nagai
YFYukihiro Furusawa
Yukihiro Furusawa
The health benefits of wheat-derived arabinoxylan, a commonly consumed dietary fiber, have been studied for decades. However, its effect on the gut microenvironment and inflammatory bowel disease remains unclear. The objective of this study was to understand the effect of wheat-derived arabinoxylan on gut microbiota, colonic regulatory T cells (Tregs), and experimental colitis. In this study, healthy and chronic colitis model mice were fed chow containing cellulose or wheat-derived arabinoxylan for 2–6 weeks and subjected to subsequent analysis. A 16S-based metagenomic analysis of the fecal DNA revealed that Lachnospiraceae, comprising butyrate-producing and Treg-inducing bacteria, were overrepresented in arabinoxylan-fed mice. In line with the changes in the gut microbiota, both the fecal butyrate concentration and the colonic Treg population were elevated in the arabinoxylan-fed mice. In a T cell transfer model of chronic colitis, wheat-derived arabinoxylan ameliorated body weight loss and colonic tissue inflammation, which may, in part, be mediated by Treg induction. Moreover, wheat-derived arabinoxylan suppressed TNFα production from type 1 helper T cells in this colitis model. In conclusion, wheat-derived arabinoxylans, by altering the gut microenvironment, may be a promising prebiotic for the prevention of colitis.

8 June 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SIShinichi Ikushiro
Shinichi Ikushiro
MNMiyu Nishikawa
Miyu Nishikawa
YMYuuka Masuyama
Yuuka Masuyama
TSTadashi Shouji
Tadashi Shouji
MFMiharu Fujii
Miharu Fujii
TSToshiyuki Sakaki
Toshiyuki Sakaki

1 January 2013 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
KYKaori Yasuda
Kaori Yasuda
SIShinichi Ikushiro
Shinichi Ikushiro
MKMasaki Kamakura
Masaki Kamakura
MTMasashi Takano
Masashi Takano
NSNozomi Saito
Nozomi Saito
Toshiyuki SakakiToshiyuki Sakaki
Toshiyuki Sakaki

13 November 2017 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
MNMiyu Nishikawa
Miyu Nishikawa
YMYuuka Masuyama
Yuuka Masuyama
MNMotomichi Nunome
Motomichi Nunome
KYKaori Yasuda
Kaori Yasuda
TSToshiyuki Sakaki
Toshiyuki Sakaki
SIShinichi Ikushiro
Shinichi Ikushiro

1 January 2006 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
SIShinichi Ikushiro
Shinichi Ikushiro
YEYoshikazu Emi
Yoshikazu Emi
YKYoshihisa Kato
Yoshihisa Kato
SYShizuo Yamada
Shizuo Yamada
TSToshiyuki Sakaki
Toshiyuki Sakaki
Expression of UDP-glucuronosyltransferases (UGT) in mammals is thought to be regulated in both a tissue- and developmental-specific manner. Furthermore, induction of genes encoding UGT occurs after exposure to xenobiotics including drugs, environmental pollutants and dietary compounds. In human, isoforms of UGT 1A subfamily catalyze the glucuronidation of a greater proportion of drugs, suggesting that the expression of UGT1A isoforms is responsible for the clearance of a diverse range of drugs. To analyze the expression of human UGT1A isoforms, we have developed polyclonal antibodies against specific peptide regions within the isoforms (UGT1A1, 1A3, 1A4, 1A6 and 1A9). The prepared antipeptide antibodies were found to be highly monospecific for each UGT1A isoform and no cross-reactivity with UGT2B isoforms was detected. Analysis of UGT1A protein levels in hepatic microsomes using these antibodies demonstrated interindividual differential expression of each isoform. These highly specific antipeptide antibodies provide an important tool to analyze tissue distribution and interindividual expression levels of human UGT1As.